CREDE CAPITAL GROUP BUYS 10% OF FRENCH BIOTECH COMPANY, HYBRIGENICS; STOCK RISES 72%

Paris, 28 October 2014 – Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases and specialised in proteomic and genomic scientific services, today announces the successful completion of a private placement for $6 million to the Crede Capital Group, llc, a US-based family office, which has completed numerous investments in European life sciences companies. Terren Peizer, Chairman of Crede Capital Group, his personal investment vehicle, commented, “We are gratified that the market is recognizing what we believe; that Hybigenics’ vitamin D receptor agonist  represents an important drug candidate for the treatment of castrate resistant prostate cancer. We are proud to provide the Company with the capital to commercialize this intriguing drug candidate.”

A total of 3,500,000 new shares have been issued at €1.32 each, representing a 20% discount to the 5-day volume weighted average price of Hybrigenics shares prior to the operation which was completed on the basis of the delegation in place according to the 11th resolution voted by the Shareholders’ Meeting of June 20, 2014 with respect to private placements to qualified investors or to a small number of investors with the meaning of the paragraph II of article L. 411-2 of the French financial and monetary Code. The new shares are of the same class as existing shares and represent 13.5% of Hybrigenics’ capital before the capital raise and 11.9% after.
“The success of this capital increase by Crede Capital Group, a US family office, demonstrates the attractiveness of Hybrigenics. Hybrigenics combines the clinical development of inecalcitol in orphan adult leukemias, the research collaboration with Servier and the expanding business of proteomic and genomic services. This capital increase will enable Hybrigenics to strengthen its research and clinical development activities,” said Remi Delansorne, Hybrigenics’ CEO.

About Hybrigenics
Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases and providing cutting-edge proteomic and genomic scientific services.

Hybrigenics’ current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol has also been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

Hybrigenics Services (www.hybrigenics-services.com) is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform.

Helixio (www.helixio.com), Hybrigenics’ genomic branch, provides state-of-the-art services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing with an Illumina NextSeq500. Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.

Crede Capital’s Catasys, Inc. market value soars to over $100 million on Seeking Alpha Report.

Crede Capital Group’s 69% owned Catasys, Inc.’s market value soared to over $100 million on a Seeking Alpha Report. Terren Peizer, Chairman of Crede Capital, his personal investment vehicle, and Founder, Chairman, and CEO of Catasys, Inc., commented, “This coming year we should begin to demonstrate that we are in the process of significantly changing the Behavioral Health Industry; as the recent widely reported tragic deaths of Seymour Hoffman and Robin Williams point out the incredible need to do so. With every mass school killing; with every movie theater mass killing, the conversation has been gradually shifting from NRA issues to the broken Behavioral Healthcare System.  We are certainly the pioneer and leader in this effort. We were the first to identify the
problem , quantify the problem, provide a solution, and incentivise Health Insurance companies to pay for 100% of the treatment costs that patients need to improve both behavioral and physical medical health. Heretofore, healthcare insurance companies covered minimal behavioral health claims and costs, unlike the coverage for other diseases like oncological and cardiovascular diseases. Over the next three years, we expect to cover over 100 million lives and emerge as the defacto standard for Behavioral Health treatment and care. ”

Catasys’ Unique Delivery Of Cost Savings To Insurers Could Drive Significant Upside Within 12 Months
Catasys (OTCQB:CATS) is an emerging growth…
SEEKINGALPHA.COM

22nd Century Group, Inc.’s stock rises 21% on Crede Capital Group’s additional $10 million Investment

CLARENCE, N.Y. – 22nd Century Group, Inc. (NYSE MKT: XXII) announced today that it has closed a private placement with Crede CG III, Ltd (Crede), pursuant to which 22nd Century sold 3,871,767 shares of restricted stock for the purchase price of $10,000,000. The pricing was determined by the 3-day volume-weighted average price (VWAP) from September 10 through 12. Proceeds of the financing will be used to conduct exposure studies, product launches, acquisitions, potential joint ventures, and for general working capital purposes. As one of the largest shareholders of the Company, Crede continues to demonstrate its long-term investment horizon by investing new money in restricted common stock of 22nd Century Group at current market prices – without a discount. Terren Peizer, Chairman of Crede Capital Group, his personal investment vehicle, commented, ” We are delighted to have the opportunity to increase our stake in 22nd Century Group. We strongly believe that their important technology, which modulates nicotine and tar in tobacco, has the potential to be the first FDA approved “modified-risk” cigarette, and become the industry standard. As 22nd Century’s largest shareholder, we look forward to supporting the company in achieving its strategic objectives.”

Joseph Pandolfino, Founder and CEO of 22nd Century Group, stated, “Crede has been a long-term shareholder and is assisting the Company in achieving its strategic objectives. Additionally, Crede has been instrumental in our Asian strategic initiatives and we are hopeful these lead to attractive opportunities for 22nd Century in the coming weeks.”

“The proceeds from this private placement will greatly strengthen our balance sheet. Further, the funds will facilitate several R&D catalysts as well as the achievement of revenue-generating milestones,” explained John T. Brodfuehrer, 22nd Century’s CFO. He added, “I expect the coming months to be very exciting for our shareholders.”

For additional information, please visit: www.xxiicentury.com

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company whose proprietary technology through genetic engineering and plant breeding allows (i) the level of nicotine (and other nicotinic alkaloids) in the tobacco plant to be decreased or increased and (ii) the levels of cannabinoids to be decreased or increased in addition to the cannabinoid profile being tailored. 22nd Century owns or is the exclusive licensee of 129 issued patents in 78 countries plus an additional 51 pending patent applications, and 22nd Century has co-exclusive rights to another 16 patent applications. Goodrich Tobacco is focused on commercial tobacco products and potential less harmful cigarettes. Botanical Genetics is focused on natural, safe and effective cannabis-based products for human health, well-being and nutrition, in addition to industrial products refined from cannabis. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development.